Eli Lilly down 19% in May, worst month since 2009. Underperformed S&P 500 by 24%, worst since August 2000. June shows promise, historically Lilly’s strongest month. See how Matt Maley is ...

Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its diabetes treatment Mounjaro, escalating its battle against unauthorized ...

April 23 (UPI) --Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling compounds of slightly-different versions of Lilly drugs ...

Eli Lilly has seen its top line grow at an average rate of 17.4% over the last 3 years (vs. increase of 6.2% for S&P 500) Its revenues have grown 32.0% from $34 Bil to $45 Bil in the last 12 ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for diabetes and weight loss. Latest U.S.

It's Thursday morning, 11:50 a.m. ET -- and Eli Lilly (NYSE: LLY) stock is off to the races! This morning, the Indianapolis-based pharmaceutical giant announced that its new GLP-1 weight loss pill ...

Eli Lilly stock surged as much as 17% after positive phase-three trial data came out for orforglipron. It found orforglipron, a GLP-1 weight-loss pill, led to significant weight and A1C reductions.

Eli Lilly announced a successful Phase 3 clinical trial of its new GLP-1 weight loss drug, orforglipron, which comes in pill form -- not an injection. This first trial showed weight loss of 7.9% ...

Here’s what to know about Eli Lilly’s pill, which still must go through a review process by the Food and Drug Administration to be approved for sale. When will the pill become available?

Eli Lilly's stock boomed April 17 after announcing a new experimental pill that caused nearly 8% weight loss at certain dosages and lowered blood sugar in patients during a clinical trial.. The ...

Eli Lilly's R&D portfolio includes 77 projects, 22 of which are in Phase 3. At the same time, Novo has 47 projects , three of which have been submitted to regulators for approval, and 12 are in ...